Effects of SORL1 gene on Alzheimer's disease. focus on gender, neuropsychiatric symptoms and pro-inflammatory cytokines

Current Alzheimer Research

Volumn 10, Issue 2, 2013, Pages 154-164

  Olgiati, Paolo ^a   Politis, Antonis ^b   Albani, Diego ^c   Rodilossi, Serena ^c   Polito, Letizia ^c,f   Zisaki, Aikaterini ^d   Piperi, Christina ^d   Liappas, Ioannis ^b   Stamouli, Evangelia ^b   Mailis, Antonis ^b   Batelli, Sara ^c   Forloni, Gianluigi ^c   Marsano, Agnese ^a   Balestri, Martina ^a   Soldatos, Costantine R ^b   de Ronchi, Diana ^a   Kalofoutis, Anastasios ^e   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^f Golgi Cenci Research Center   (Italy)

Author keywords

Alzheimer; Gender; Inflammatory cytokines; Psychosis; SORL1

Indexed keywords

APOLIPOPROTEIN E; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

5' UNTRANSLATED REGION; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; CONTROLLED STUDY; CORNELL SCALE FOR DEPRESSION IN DEMENTIA; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENDER; GENE; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHIATRIC INVENTORY; NEUROPSYCHIATRY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SINGLE NUCLEOTIDE POLYMORPHISM; SORL1 GENE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; CYTOKINES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MALE; MEMBRANE TRANSPORT PROTEINS; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SEX CHARACTERISTICS;

EID: 84874866344     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310020005     Document Type: Article

References (96)

1. Ritchie K, Lovestone S. The dementias. Lancet 360: 1759-66 (2002).
2. Tandon A, Rogaeva E, Mullan M, St George-Hyslop PH. Molecular genetics of Alzheimer's disease: the role of beta-amyloid and the presenilins. Curr Opin Neurol 13: 377-84 (2000).
3. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 115: 1121-9 (2005).
4. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 113: 1857-70 (2000).
5. Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA 102: 13461-6 (2005).
6. Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI, et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci 26: 1596-603 (2006).
7. Jacobsen L, Madsen P, Moestrup SK, Lund AH, Tommerup N, Nykjaer A, et al. Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-macroglobulin receptorassociated protein. J Biol Chem 271: 31379-83 (1996).
8. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39: 168-77 (2007).
9. Lee JH, Chulikavit M, Pang D, Zigman WB, Silverman W, Schupf N. Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome. Neurosci Lett 425: 105-9 (2007).
10. Meng Y, Lee JH, Cheng R, St George-Hyslop P, Mayeux R, Farrer LA. Association between SORL1 and Alzheimer's disease in a genome-wide study. Neuroreport 18: 1761-4 (2007).
11. Tan EK, Lee J, Chen CP, Teo YY, Zhao Y, Lee WL. SORL1 haplotypes modulate risk of Alzheimer's disease in Chinese. Neurobiol Aging 30: 1048-51 (2009).
12. Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, Sleegers K. SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum Mutat 29: 769-70 (2008).
13. Lee JH, Shibata N, Cheng R, Mayeux R. Possible association between SORL1 and Alzheimer disease? Reanalysing the data of Shibata et al. Dement Geriatr Cogn Disord 26: 482 (2008).
14. Kimura R, Yamamoto M, Morihara T, Akatsu H, Kudo T, Kamino K, et al. SORL1 is genetically associated with Alzheimer disease in a Japanese population. Neurosci Lett 461: 177-80 (2009).
15. Minster RL, DeKosky ST, Kamboh MI. No association of SORL1 SNPs with Alzheimer's disease. Neurosci Lett 440: 190-2 (2008).
16. Liu F, Ikram MA, Janssens AC, Schuur M, de Koning I, Isaacs A, et al. A Study of the SORL1 Gene in Alzheimer's Disease and Cognitive Function. J Alzheimers Dis: (2009).
17. Cellini E, Tedde A, Bagnoli S, Pradella S, Piacentini S, Sorbi S, et al. Implication of sex and SORL1 variants in italian patients with Alzheimer disease. Arch Neurol 66: 1260-6 (2009).
18. Xu H, Wang R, Zhang Y, Zhang X. Estrogen, beta-amyloid metabolism/trafficking, and Alzheimer's disease. Ann NY Acad Sci 1089: 324-342 (2006).
19. Borroni B, Grassi M, Costanzi C, Zanetti M, Archetti S, Franzoni S, et al. Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease. Neurobiol Aging: Epub ahead of print (2006).
20. Ueki A, Ueno H, Sato N, Shinjo H, Morita Y. Serotonin transporter gene polymorphism and BPSD in mild Alzheimer's disease. J Alzheimers Dis 12: 245-53 (2007).
21. Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimer's disease. Dement Geriatr Cogn Disord 26: 257-60 (2008).
22. McCulley MC, Day IN, Holmes C. Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 124: 50-3 (2004).
23. Serretti A, Olgiati P, Politis A, Malitas P, Albani D, Dusi S, et al Lack of association between interleukin-1 alpha rs1800587 polymorphism and Alzheimer's disease in two Independent European samples. J Alzheimers Dis 16: 181-7 (2009).
24. Rogers J. The inflammatory response in Alzheimer's disease. J Periodontol 79: 1535-43 (2008).
25. Hermey G, Sjogaard SS, Petersen CM, Nykjaer A, Gliemann J Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members. Biochem J 395: 285-93 (2006).
26. Zhao Y, Cui JG, Lukiw WJ. Reduction of sortilin-1 in Alzheimer hippocampus and in cytokine-stressed human brain cells. Neuroreport 18: 1187-91 (2007).
27. American Psychiatric Association 2002, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised., American Psychiatric Association, Washington DC.
28. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-98 (1975).
29. Mungas D, Reed BR, Ellis WG, Jagust WJ. The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol 58: 1243-7 (2001).
30. Cummings J, Mega M, Gray K, Rosenberg-Thompson S, Carusi D, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314 (1994).
31. Binetti G, Mega M, Magni E, Padovani A, Rozzini L, Bianchetti A, et al. Behavioral disorders in Alzheimer disease: a transcultural perspective. Arch Neurol 55: 539-544 (1998).
32. Benoit M, Dygai I, Migneco O, Robert P, Bertogliati C, Darcourt J, et al. Behavioral and psychological symptoms in Alzheimer's disease. Relation between apathy and regional cerebral perfusion. Dement Geriatr Cogn Disord 10: 511-517 (1999).
33. Vilalta-Franch J, Lozano-Gallego M, Hernandez-Ferrandiz M, Llinas-Regla J, Lopez-Pousa S, Lopez O. The Neuropsychiatric Inventory. Psychometric properties of its adaptation into Spanish. Rev Neurol 29: 15-19 (1999).
34. Politis AM, Mayer LS, Passa M, Maillis A, Lyketsos CG. Validity and reliability of the newly translated Hellenic Neuropsychiatric Inventory (H-NPI) applied to Greek outpatients with Alzheimer's disease: a study of disturbing behaviors among referrals to a memory clinic. Int J Geriatr Psychiatry 19: 203-8 (2004).
35. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry 23: 271-84 (1988).
36. Camus V, Schmitt L, Ousset P, Micas M. Depression and dementia: contribution to the French validation of 2 depression scales: the Cornell Scale for Depression in Dementia and the Dementia Mood Assessment Scale. Encephale 21: 201-208 (1995).
37. Pujol J, De Azpiazu P, Salamero M, Cuevas R. Depressive symptoms in dementia. The Cornell scale: validation of the Spanish version. Rev Neurol 33: 397-398 (2001).
38. World-health-organization 1990, Composite International Diagnostic Interview.
39. Silverman JM, Li G, Schear S, Wang ZX, Sotolongo C, Somary K, et al. A cross-cultural family history study of primary progressive dementia in relatives of nondemented elderly Chinese, Italians, Jews and Puerto Ricans. Acta Psychiatr Scand 85: 211-7 (1992).
40. Li G, Aryan M, Silverman JM, Haroutunian V, Perl DP, Birstein S, et al. The validity of the family history method for identifying Alzheimer disease. Arch Neurol 54: 634-40 (1997).
41. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 11: (1955).
42. Eustace A, Coen R, Walsh C, Cunningham CJ, Walsh JB, Coakley D, et al. A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer's disease. Int J Geriatr Psychiatry 17: 968-73 (2002).
43. Piccininni M, Di Carlo A, Baldereschi M, Zaccara G, Inzitari D Behavioral and psychological symptoms in Alzheimer's disease: frequency and relationship with duration and severity of the disease. Dement Geriatr Cogn Disord 19: 276-81 (2005).
44. van der Vlies AE, Pijnenburg YA, Koene T, Klein M, Kok A, Scheltens P, et al. Cognitive impairment in Alzheimer's disease is modified by APOE genotype. Dement Geriatr Cogn Disord 24: 98-103 (2007).
45. Zdanys KF, Kleiman TG, MacAvoy MG, Black BT, Rightmer TE, Grey M, et al. Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease. Neuropsychopharmacology 32: 171-9 (2007).
46. Persson CM, Wallin AK, Levander S, Minthon L. Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil. BMC Neurol 9: 7 (2009).
47. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 21: 813-24 (2009).
48. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol 8: 131-6 (2001).
49. Angelopoulos P, Agouridaki H, Vaiopoulos H, Siskou E, Doutsou K, Costa V, et al. Cytokines in Alzheimer's disease and vascular dementia. Int J Neurosci 118: 1659-72 (2008).
50. Olgiati P, Politis A, Malitas P, Albani D, Dusi S, Polito L, et al APOE epsilon-4 allele and cytokine production in Alzheimer's disease. Int J Geriatr Psychiatry: (2009).
51. Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, et al Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the proinflammatory and anti-inflammatory cytokines. J Neuroimmunol 148: 162-71 (2004).
52. Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp Gerontol 40: 165-71 (2005).
53. Nizri E, Irony-Tur-Sinai M, Faranesh N, Lavon I, Lavi E, Weinstock M, et al. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 203: 12-22 (2008).
54. Cohen J 1988, Statistical power analysis for the behavioral sciences, Lawrence Erlbaum Associates, Hillsdale, New Jersey, pp. 8-14.
55. Faul F, Erdfelder E, Lang A, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191 (2007).
56. Lee JH, Barral S, Reitz C. The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer's disease. Curr Neurol Neurosci Rep 8: 384-91 (2008).
57. Lee JH, Cheng R, Schupf N, Manly J, Lantigua R, Stern Y, et al The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol 64: 501-6 (2007).
58. Li Y, Rowland C, Catanese J, Morris J, Lovestone S, O'Donovan MC, et al. SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol Dis 29: 293-6 (2008).
59. Reynolds CA, Hong MG, Eriksson UK, Blennow K, Johansson B, Malmberg B, et al. Sequence variation in SORL1 and dementia risk in Swedes. Neurogenetics: (2009).
60. Pike CJ, Carroll JC, Rosario ER, Barron AM. Protective actions of sex steroid hormones in Alzheimer's disease. Frontiers in neuroendocrinology 30: 239-58 (2009).
61. Tang M, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348: 429-32 (1996).
62. Morinaga A, Hirohata M, Ono K, Yamada M. Estrogen has antiamyloidogenic effects on Alzheimer's beta-amyloid fibrils in vitro. Biochemical and biophysical research communications 359: 697-702 (2007).
63. Greenfield J, Leung L, Cai D, Kaasik K, Gross R, Rodriguez-Boulan E, et al. Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis. J Biol Chem 277: 12128-36 (2002).
64. Woods DL, Bushnell B, Kim H, Geschwind D, Cummings J. Apolipoprotein epsilon4 status is associated with behavioral symptoms in nursing home residents with dementia. Int Psychogeriatr 21: 722-8 (2009).
65. Del Prete M, Spaccavento S, Craca A, Fiore P, Angelelli P. Neuropsychiatric symptoms and the APOE genotype in Alzheimer's disease. Neurol Sci: (2009).
66. Sukonick D, Pollock B, Sweet R, Mulsant B, Rosen J, Klunk W, et al. The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease. Arch Neurol 58: 1425-1428 (2001).
67. Sweet RA, Pollock BG, Sukonick DL, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr 13: 401-9 (2001).
68. Sweet R, Devlin B, Pollock B, Sukonick D, Kastango K, Bacanu S, et al. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol Psychiatry 10: 1026-1036 (2005).
69. Cuenco K, Lunetta K, Baldwin C, McKee A, Guo J, Cupples L, et al. Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol 65: 1640-8 (2008).
70. Chen H, Wilkins L, Aziz N, Cannings C, Wyllie D, Bingle C, et al Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet 15: 519-29 (2006).
71. Katila H, Hänninen K, Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol Psychiatry 4: 179-81 (1999).
72. Zanardini R, Bocchio-Chiavetto L, Scassellati C, Bonvicini C, Tura G, Rossi G, et al. Association between IL-1beta -511C/T and IL1RA (86bp)n repeats polymorphisms and schizophrenia. J Psychiatr Res 37: 457-462 (2003).
73. Craig D, Hart DJ, McCool K, McIlroy SP, Passmore AP. The interleukin 1beta gene promoter polymorphism (-511) acts as a risk factor for psychosis in Alzheimer's dementia. Ann Neurol 56: 121-4 (2004).
74. Kowalski J, Blada P, Kucia K, Madej A, Herman Z. Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr Res 50: (2001).
75. Koliaskina G, Sekirina T, Androsova L, Kushner S, Vasil'eva E, Burbaeva O, et al. The influence of atypical neuroleptics on the immune system of patients with schizophrenia]. Vestn Ross Akad Med Nauk 3: 14-19 (2007).
76. Higuchi M, Hatta K, Honma T, Hitomi YH, Kambayashi Y, Hibino Y, et al. Association between altered systemic inflammatory interleukin-1beta and natural killer cell activity and subsequently agitation in patients with Alzheimer disease. Int J Geriatr Psychiatry 25: 604-11 (2009).
77. Tachida Y, Nakagawa K, Saito T, Saido TC, Honda T, Saito Y, et al. Interleukin-1 beta up-regulates TACE to enhance alphacleavage of APP in neurons: resulting decrease in Abeta production. J Neurochem 104: 1387-93 (2008).
78. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117: 1595-604 (2007).
79. Chao CC, Ala TA, Hu S, Crossley KB, Sherman RE, Peterson PK, et al. Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol 1: 433-6 (1994).
80. Tarkowski E. Cytokines in dementias. Curr Drug Targets Inflamm Allergy 1: 193-200 (2002).
81. Lanzrein A, Johnston C, Perry V, Jobst K, King E, Smith A. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factoralpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord 12: 215-27 (1998).
82. Shalit F, Sredni B, Stern L, Kott E, Huberman M. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients. Neurosci Lett 174: 130-132 (1994).
83. Lombardi V, García M, Rey L, Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. J Neuroimmunol 97: 163-171 (1999).
84. De Luigi A, Fragiacomo C, Lucca U, Quadri P, Tettamanti M, Grazia De Simoni M. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev 122: 1985-1995 (2001).
85. Sala G, Galimberti G, Canevari C, Raggi M, Isella V, Facheris M, et al. Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol Aging 24: 909-14 (2003).
86. Richartz E, Stransky E, Batra A, Simon P, Lewczuk P, Buchkremer G, et al. Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease? J Psychiat Res 39: 535-543 (2005).
87. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68: 1902-8 (2007).
88. Craig MC, Murphy DG. Alzheimer's disease in women. Best Pract Res Clin Obstet Gynaecol 23: 53-61 (2009).
89. Craig MC, Murphy DG. Estrogen therapy and Alzheimer's dementia. Ann N Y Acad Sci 1205: 245-53 (2010).
90. Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 16: 1043-53 (2001).
91. Mok WY, Chu LW, Chung CP, Chan NY, Hui SL. The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease. Int J Geriatr Psychiatry 19: 1040-6 (2004).
92. Ryu SH, Katona C, Rive B, Livingston G. Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study. Am J Geriatr Psychiatry 13: 976-83 (2005).
93. Matsumoto N, Ikeda M, Fukuhara R, Shinagawa, Ishikawa T, Mori T, et al. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement Geriatr Cogn Disord 23: 219-24 (2007).
94. Grossberg GT. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease. Curr Med Res Opin 21: 1631-9 (2005).
95. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165: 844-54 (2008).
96. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 28: 639-47 (2007).